Allena Pharmaceuticals reports Q3 EPS (22c), consensus (21c)

"In recent months, we have continued to make progress across our portfolio. We are actively enrolling URIROX-2, our pivotal trial of reloxaliase for patients with EH. We also recently completed dosing in our Phase 1 trial of ALLN-346 and we remain on track to achieve all our expected clinical milestones," said Louis Brenner, M.D, President and Chief Executive Officer of Allena Pharmaceuticals. "In addition, at the virtual ASN meeting, we presented an aggregate review of data generated across our clinical development program for reloxaliase, which highlight reloxaliase's consistent, clinically meaningful impact on urinary oxalate excretion and reinforce our conviction in its potential as a novel therapeutic that could change the treatment paradigm in EH. Following our strategic debt financing agreement with Pontifax, we are well-funded, with the capital and financial flexibility to advance our mission and deliver on the promise of oral enzyme therapeutics for people with rare and severe metabolic and kidney diseases."